JP5529023B2 - 抗制御性t細胞抗体と磁性微粒子を含む悪性腫瘍の温熱治療用キット、及びその温熱治療法 - Google Patents
抗制御性t細胞抗体と磁性微粒子を含む悪性腫瘍の温熱治療用キット、及びその温熱治療法 Download PDFInfo
- Publication number
- JP5529023B2 JP5529023B2 JP2010527623A JP2010527623A JP5529023B2 JP 5529023 B2 JP5529023 B2 JP 5529023B2 JP 2010527623 A JP2010527623 A JP 2010527623A JP 2010527623 A JP2010527623 A JP 2010527623A JP 5529023 B2 JP5529023 B2 JP 5529023B2
- Authority
- JP
- Japan
- Prior art keywords
- kit
- mcl
- magnetic field
- tumor
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Ceramic Engineering (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
ジラウロイルホスファチジルコリン(SIGMA)9mg、ジオレイルホスファチジルエタノールアミン(SIGMA)9mg、N−(α−トリメチルアンモニオアセチル)ジドデシル−D−グルタメートクロリド(相互薬工)4.5mgを3mlのクロロホルムで溶解後、エバポレーターにて減圧乾燥し、ナス型コルベン内壁に脂質膜を作製した。これに、マグネタイト溶液(戸田工業社製)20mg/2mlを加え、脂質膜が剥離するまで、約10分間ボルテックスミキサーで処理した。これに対して、1分間の超音波処理と30秒間の氷冷下放置を繰り返し、計1時間の超音波処理を行った。リン酸緩衝液(PBS)にてpHを7.0に調節後、10,000Gで50分間、4℃で遠心分離を行い、沈殿物としてMCLを回収した後、超純水に懸濁した。
マウスCTLA4抗体のハイブリドーマ細胞(American type culture collection (ATCC) Number HB-304)を培養し、その培養液を130Gで10分間、4℃で遠心した。得られた上清を、再度、10,000Gで15分間、4℃で遠心分離し上清を採取した。この上清を氷冷し、攪拌下に100mlあたり27.7gの硫酸アンモニウムを徐々に加え溶解し1時間放置した。これを、10,000Gで5分間、4℃で遠心し、得られた沈殿物をリン酸ナトリウム緩衝液約0.8〜1.2mlで溶解後、分子量10,000でカットされる透析膜を用いて、リン酸ナトリウム緩衝液 に対して透析を2時間行った。透析終了後、10,000G、15分間、4℃で遠心し上清を得た。
悪性腫瘍の温熱治療において、より効果的に全身性の抗腫瘍免疫を誘導し、温熱治療をしていない癌病巣をも退縮せしめることを目指して、モデル実験系を作成した。
腫瘍体積(mm3)=長径(mm)×短径(mm)×短径(mm)/2
より効果的に全身性の抗腫瘍免疫を誘導せしめることにより、温熱治療をしていない癌病巣をも退縮せしめることができる温熱療法の開発を目指した。即ち、実施例3で示した動物モデルにおいて、右背部に出現した腫瘍を温熱治療することにより、温熱治療をしていない左の腫瘍に対する抗腫瘍効果を検討した。温熱治療と抗制御性T細胞抗体投与の併用治療を含む以下の4群((1)無治療群、(2)抗体投与群、(3)温熱治療群、(4)温熱治療と抗制御性T細胞抗体投与の併用群)の比較実験を行った。
Claims (15)
- (i)抗CTLA4抗体を含む薬剤;および
(ii)マグネタイトカチオニックリポソーム(MCL)を含む薬剤、ここでMCLは、Fe3O4の組成を有するマグネタイトを含み、少なくとも一つの脂質で被膜され、そしてここでMCLは、交番磁場に暴露されると発熱する、
を含む、悪性腫瘍の温熱治療用キット。 - 少なくとも一つの脂質が、正電荷脂質を含む、請求項1に記載のキット。
- MCLが、悪性腫瘍細胞に選択的に結合してMCLを悪性腫瘍細胞に標的化する抗体を結合した少なくとも一つの脂質で被膜されたFe3O4の組成を有するマグネタイトを含む、請求項1に記載のキット。
- 少なくとも一つの脂質が、ジラウロイルホスファチジルコリン(DLPC)、ジオレイルホスファチジルエタノールアミン(DIPE)、およびN−(α−トリメチルアンモニオアセチル)ジドデシル−D−グルタメートクロリド(TMAG)を含む、請求項1に記載のキット。
- 悪性腫瘍の温熱治療が、抗CTLA4抗体を含む薬剤の使用およびMCLを含む薬剤の使用を含む、請求項1に記載のキット。
- 悪性腫瘍の温熱治療が、温熱治療をすることを含み、ここで温熱治療が対象の腫瘍にMCLを含む薬剤を投与することおよび次に対象を交番磁場に暴露することを含む、請求項5に記載のキット。
- 悪性腫瘍の温熱治療が、抗CTLA4抗体を含む薬剤の投与および温熱治療をすることを同時に、または時間をおいて任意の順序で実施することを含む、請求項6に記載のキット。
- 悪性腫瘍の温熱治療が、MCLを含む薬剤を投与後、少なくとも三日、対象を交番磁場に暴露することを含む、請求項6に記載のキット。
- 悪性腫瘍の温熱治療が、MCLを含む薬剤を投与する前に抗CTLA4抗体を含む薬剤を対象に投与することを含む、請求項6に記載のキット。
- 悪性腫瘍の温熱治療が、MCLを含む薬剤を投与後および少なくとも一回の交番磁場の適用後に抗CTLA4抗体を含む薬剤を対象に投与することを含む、請求項6に記載のキット。
- 悪性腫瘍の温熱治療が、対象の交番磁場への初回暴露と同日に抗CTLA4抗体を含む薬剤およびMCLを含む薬剤を対象に投与することを含む、請求項6に記載のキット。
- 悪性腫瘍の温熱治療が、対象を交番磁場に一回の暴露あたり30分間暴露することを含む、請求項6に記載のキット。
- 悪性腫瘍の温熱治療が、対象を100KHzの周波数を有する交番磁場に暴露することを含む、請求項6に記載のキット。
- 悪性腫瘍の温熱治療が、対象の交番磁場への暴露中に腫瘍の温度をモニタリングすることを含む、請求項6に記載のキット。
- 悪性腫瘍の温熱治療が、対象の交番磁場への暴露中に交番磁場の出力を調整して腫瘍の温度を46℃に保つことを含む、請求項6に記載のキット。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2008/065983 WO2010026638A1 (ja) | 2008-09-04 | 2008-09-04 | 抗制御性t細胞抗体と磁性微粒子を含む悪性腫瘍の温熱治療用キット、及びその温熱治療法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014084151A Division JP2014144972A (ja) | 2014-04-16 | 2014-04-16 | 抗制御性t細胞抗体と磁性微粒子を含む悪性腫瘍の温熱治療用キット、及びその温熱治療法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2010026638A1 JPWO2010026638A1 (ja) | 2012-01-26 |
JP5529023B2 true JP5529023B2 (ja) | 2014-06-25 |
Family
ID=41796826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010527623A Active JP5529023B2 (ja) | 2008-09-04 | 2008-09-04 | 抗制御性t細胞抗体と磁性微粒子を含む悪性腫瘍の温熱治療用キット、及びその温熱治療法 |
Country Status (4)
Country | Link |
---|---|
US (2) | US20110165255A1 (ja) |
JP (1) | JP5529023B2 (ja) |
AU (1) | AU2008361497B2 (ja) |
WO (1) | WO2010026638A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014054884A1 (ko) * | 2012-10-05 | 2014-04-10 | 연세대학교 산학협력단 | 민감화 물질을 포함하는 온열 치료용 조성물 |
JP2016537034A (ja) | 2013-09-20 | 2016-12-01 | 第一高周波工業株式会社 | 磁束照射装置および構成要素 |
JP2016187364A (ja) | 2013-09-20 | 2016-11-04 | 第一高周波工業株式会社 | 磁束照射装置 |
WO2016141051A1 (en) | 2015-03-02 | 2016-09-09 | KAIO Therapy, LLC | Systems and methods for providing alternating magnetic field therapy |
CA3066742A1 (en) | 2017-06-13 | 2018-12-20 | Houn Simon Hsia | Compositions and methods for enhancing hyperthermia therapy |
CN107389937A (zh) * | 2017-07-20 | 2017-11-24 | 上海长海医院 | 一种快速检测体液中肿瘤细胞的试剂盒及其检测方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03128331A (ja) * | 1989-07-03 | 1991-05-31 | Takeshi Kobayashi | 腫瘍の温熱療法に使用する、抗体が結合した磁性微粒子 |
WO1997027876A1 (en) * | 1996-02-02 | 1997-08-07 | Sidney Kimmel Cancer Center | Immunotherapy sensitization of cancer therapy |
JP2006306824A (ja) * | 2005-03-31 | 2006-11-09 | Univ Of Tsukuba | 腫瘍壊死誘導療法の抗腫瘍効果増強剤 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19937492C2 (de) * | 1999-08-07 | 2001-08-23 | Mfh Hyperthermiesysteme Gmbh | Magnetfeldapplikator zur Aufheizung von magnetischen oder magnetisierbaren Substanzen oder Festkörpern in biologischem Gewebe |
DE19937493C2 (de) * | 1999-08-07 | 2001-06-07 | Mfh Hyperthermiesysteme Gmbh | Magnetfeldapplikator zur Aufheizung von magnetischen oder magnetisierbaren Substanzen oder Festkörpern in biologischem Gewebe |
DE10109105C2 (de) * | 2001-02-24 | 2003-01-09 | Mfh Hyperthermiesysteme Gmbh | Magnetspulenanordnung eines Magnetfeldapplikators zur Aufheizung von magnetischen oder magnetisierbaren Substanzen oder Festkörpern in biologischem Gewebe |
EP1438971A4 (en) * | 2001-10-25 | 2005-01-12 | Ttc Co Ltd | IMMUNE AMPLIFIERS IN THERAPEUTIC THERAPY IN CANCER |
US7282479B2 (en) * | 2003-03-31 | 2007-10-16 | Ttc Co., Ltd. | Hyperthermia agent for malignant tumor comprising cytokine and magnetic fine particles |
US20050107870A1 (en) * | 2003-04-08 | 2005-05-19 | Xingwu Wang | Medical device with multiple coating layers |
US20050090732A1 (en) * | 2003-10-28 | 2005-04-28 | Triton Biosystems, Inc. | Therapy via targeted delivery of nanoscale particles |
CN100577210C (zh) * | 2004-03-17 | 2010-01-06 | 学校法人东海大学 | 利用免疫应答系统的药物传递系统 |
DE102005016873A1 (de) * | 2005-04-12 | 2006-10-19 | Magforce Nanotechnologies Ag | Nanopartikel-Wirstoff-Konjugate |
US7670676B2 (en) * | 2005-06-15 | 2010-03-02 | Toda Kogyo Corporation | Pharmaceutical raw material |
US8214053B2 (en) * | 2006-08-29 | 2012-07-03 | Nanotherapy Co., Ltd. | Body heating device |
DE102008003615A1 (de) * | 2008-01-09 | 2009-07-16 | Magforce Nanotechnologies Ag | Magnetische Transducer |
DE102008008522A1 (de) * | 2008-02-11 | 2009-08-13 | Magforce Nanotechnologies Ag | Implantierbare Nanopartikel-enthaltende Produkte |
ES2371210T3 (es) * | 2008-03-28 | 2011-12-28 | Magforce Nanotechnologies Ag | Dispositivo de aplicaciã“n de campo magnã‰tico alterno para el calentamiento de sustancias magnã‰ticas o magnetizables en tejido biolã“gico. |
US20120225123A1 (en) * | 2009-11-09 | 2012-09-06 | University Health Network | Use of Synergistic Combinations of an Avermectin and an Antineoplastic Compounds for the Treatment of Hematological Malignancies |
DE102009058769A1 (de) * | 2009-12-16 | 2011-06-22 | MagForce Nanotechnologies AG, 10589 | Temperaturabhängige Aktivierung von katalytischen Nukleinsäuren zur kontrollierten Wirkstofffreisetzung |
-
2008
- 2008-09-04 AU AU2008361497A patent/AU2008361497B2/en active Active
- 2008-09-04 WO PCT/JP2008/065983 patent/WO2010026638A1/ja active Application Filing
- 2008-09-04 US US13/062,033 patent/US20110165255A1/en not_active Abandoned
- 2008-09-04 JP JP2010527623A patent/JP5529023B2/ja active Active
-
2014
- 2014-12-19 US US14/576,852 patent/US20150119961A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03128331A (ja) * | 1989-07-03 | 1991-05-31 | Takeshi Kobayashi | 腫瘍の温熱療法に使用する、抗体が結合した磁性微粒子 |
WO1997027876A1 (en) * | 1996-02-02 | 1997-08-07 | Sidney Kimmel Cancer Center | Immunotherapy sensitization of cancer therapy |
JP2006306824A (ja) * | 2005-03-31 | 2006-11-09 | Univ Of Tsukuba | 腫瘍壊死誘導療法の抗腫瘍効果増強剤 |
Non-Patent Citations (2)
Title |
---|
JPN6013021076; Nat.Rev.Cancer Vol.7, 2007, p.95-106 * |
JPN6013021077; Jpn.J.Cancer Res. Vol.89, 1998, p.775-782 * |
Also Published As
Publication number | Publication date |
---|---|
US20150119961A1 (en) | 2015-04-30 |
US20110165255A1 (en) | 2011-07-07 |
WO2010026638A1 (ja) | 2010-03-11 |
AU2008361497A1 (en) | 2010-03-11 |
JPWO2010026638A1 (ja) | 2012-01-26 |
AU2008361497B2 (en) | 2014-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ito et al. | Complete regression of mouse mammary carcinoma with a size greater than 15 mm by frequent repeated hyperthermia using magnetite nanoparticles | |
Ito et al. | Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia | |
JP5529023B2 (ja) | 抗制御性t細胞抗体と磁性微粒子を含む悪性腫瘍の温熱治療用キット、及びその温熱治療法 | |
Shinkai et al. | Targeting hyperthermia for renal cell carcinoma using human MN antigenspecific magnetoliposomes | |
JP4576005B2 (ja) | 腫瘍および炎症性疾患を選択的に治療するために用いられる、壊死を引き起こす物質と、壊死により活性化される物質との組み合わせ | |
RU2019110071A (ru) | Способы лечения злокачественных новообразований, экспрессирующих pd-l1 | |
AU2012273182A1 (en) | Focused radiation for augmenting immune-based therapies against neoplasms | |
WO1992007466A1 (en) | Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents | |
WO2021182573A1 (ja) | 癌の治療及び/又は予防のための医薬品 | |
Chi et al. | Putative abscopal effect in three patients treated by combined radiotherapy and modulated electrohyperthermia | |
Zeng et al. | Comparison between radioimmunotherapy and external beam radiation therapy for patients with hepatocellular carcinoma | |
JP2015096065A5 (ja) | ||
RU2014145841A (ru) | Терапевтический биопрепарат для лечения гепатоцеллюлярной карциномы | |
UA124572C2 (uk) | Наночастинки для застосування як терапевтичної вакцини | |
JP4734006B2 (ja) | 抗hmw−maa抗体を結合した磁性微粒子を含むリポソーム | |
JP2014144972A (ja) | 抗制御性t細胞抗体と磁性微粒子を含む悪性腫瘍の温熱治療用キット、及びその温熱治療法 | |
Aarts et al. | Timing of adjuvant radioimmunotherapy after cytoreductive surgery in experimental peritoneal carcinomatosis of colorectal origin | |
Lukas et al. | Immune priming with spatially fractionated radiation therapy | |
WO2021182571A1 (ja) | 癌の治療及び/又は予防のための医薬品 | |
JP2018532757A (ja) | 悪性疾患に対する併用療法 | |
ITO et al. | Complete regression of hereditary melanoma in a mouse model by repeated hyperthermia using magnetite cationic liposomes | |
US20130323167A1 (en) | Detecting and treating solid tumors through selective disruption of tumor vasculature | |
JPWO2004087208A1 (ja) | 熱ショックタンパク質と磁性微粒子からなる悪性腫瘍の温熱治療剤 | |
Boustani et al. | Anti-PD-1/Anti-PD-L1 Drugs and Radiation Therapy: Combinations and Optimization Strategies. Cancers 2021, 13, 4893 | |
JPWO2005079843A1 (ja) | 新規リポソーム |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130507 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130705 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130910 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131108 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131203 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140110 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140318 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140416 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5529023 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |